Cargando…

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

PURPOSE: Recent reports indicate that refractory central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib administration. We describe a Japanese woman with NSCLC and CNS metastases who was resistant to 75 mg daily erlotinib, but t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Togashi, Yosuke, Masago, Katsuhiro, Fukudo, Masahide, Tsuchido, Yasuhiro, Okuda, Chiyuki, Kim, Young Hak, Ikemi, Yasuaki, Sakamori, Yuichi, Mio, Tadashi, Katsura, Toshiya, Mishima, Michiaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180562/ https://www.ncbi.nlm.nih.gov/pubmed/21681573 http://dx.doi.org/10.1007/s00280-011-1691-z

Ejemplares similares

Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
por: Masago, Katsuhiro, et al.
Publicado: (2010)

Continuous morphine infusion for end-stage lung cancer patients
por: KIM, YOUNG HAK, et al.
Publicado: (2013)

Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer
por: TOGASHI, YOSUKE, et al.
Publicado: (2013)

Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer
por: Fukuhara, Akiko, et al.
Publicado: (2010)

Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy
por: Fujita, Shiro, et al.
Publicado: (2010)

Concomitant T790M mutation and small‐cell lung cancer transformation after acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor
por: Fujita, Kohei, et al.
Publicado: (2016)

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2017)

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
por: Masago, Katsuhiro, et al.
Publicado: (2015)

Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton System
por: Fujita, Shiro, et al.
Publicado: (2017)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
por: Kuriyama, Yuka, et al.
Publicado: (2013)

Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer
por: Fujita, Shiro, et al.
Publicado: (2015)

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial
por: Fujita, Shiro, et al.
Publicado: (2012)

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?
por: Kim, Young Hak, et al.
Publicado: (2011)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
por: Togashi, Yosuke, et al.
Publicado: (2014)

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma
por: Tsuji, Takahiro, et al.
Publicado: (2015)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report
por: SHIMA, HIROSHI, et al.
Publicado: (2016)

Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
por: Tanaka, Shiro, et al.
Publicado: (2011)

Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Masago, Katsuhiro, et al.
Publicado: (2018)

Free energy landscape of RNA binding dynamics in start codon recognition by eukaryotic ribosomal pre-initiation complex
por: Kameda, Takeru, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography
por: Ito, Isao, et al.
Publicado: (2009)

Preliminary Evaluation of a Sitafloxacin-Containing Regimen for Relapsed or Refractory Pulmonary Mycobacterium avium Complex Disease
por: Fujita, Kohei, et al.
Publicado: (2016)

Alteration of DNA mismatch repair capacity underlying the co-occurrence of non-small-cell lung cancer and nonmedullary thyroid cancer
por: Fujita, Shiro, et al.
Publicado: (2021)

Effect of Coronavirus Disease 2019 Vaccine-Related Lymphadenopathy on Lung Cancer Treatment
por: Masago, Katsuhiro, et al.
Publicado: (2022)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
por: Doyle, Sean P, et al.
Publicado: (2018)

Mathematical-model-guided development of full-thickness epidermal equivalent
por: Kumamoto, Junichi, et al.
Publicado: (2018)

Biopsy of palliative lesions following radiotherapy
por: Fujita, Shiro, et al.
Publicado: (2019)

Surgical perception of lower tracheal or carinal resection
por: Sugita, Yusuke, et al.
Publicado: (2021)

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
por: Nadal, Ernest, et al.
Publicado: (2021)

Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review
por: Jazieh, Abdul-Rahman, et al.
Publicado: (2013)

Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7
por: Kalinowski, Felicity C., et al.
Publicado: (2012)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
por: Jabbari, Siavash, et al.
Publicado: (2011)

Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor
por: Nishimura, Toshio, et al.
Publicado: (2015)

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
por: Wang, Jack P., et al.
Publicado: (2015)

Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine
por: Akiyama, Norimichi, et al.
Publicado: (2017)

Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib
por: Amri, Jamal, et al.
Publicado: (2019)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer
por: Komiya, Natsuko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6tvcjv00v9r6qe87kn5udhvajr